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Background: Men who have sex with men (MSM) are at 
risk of HIV and are an important population to monitor 
and ameliorate combination prevention efforts. Aim: 
To estimate HIV prevalence and identify factors associ-
ated with frequent HIV testing (≥ 2 HIV tests in the last 
year) and pre-exposure prophylaxis (PrEP) use among 
MSM in London. Methods: For this cross-sectional 
study, MSM recruited from 22 social venues provided 
oral-fluid samples for anonymous HIV antibody (Ab) 
testing and completed a questionnaire. Factors asso-
ciated with frequent HIV testing and PrEP use were 
identified through logistic regression. Results: Of 767 
men recruited, 545 provided an eligible oral speci-
men. Among these, 38 MSM (7.0%) were anti-HIV posi-
tive including five (13.2%; 5/38) who reported their 
status as negative. Condomless anal sex within the 
previous 3 months was reported by 60.1% (412/685) 
men. Frequent HIV testing was associated with, in 
the past year, a reported sexually transmitted infec-
tion (adjusted odds ratio (AOR): 5.05; 95% confidence 
interval (CI): 2.66–9.58) or ≥ 2 casual condomless 
partners (AOR 2–4 partners: 3.65 (95% CI: 1.87–7.10); 
AOR 5–10 partners: 3.34 (95% CI: 1.32–8.49). 
Age ≥ 35 years was related to less frequent HIV test-
ing (AOR 35–44 years: 0.34 (95% CI: 0.16–0.72); AOR 
≥ 45 years: 0.29 (95% CI: 0.12–0.69). PrEP use in the 
past year was reported by 6.2% (46/744) of MSM and 
associated with ≥ 2 casual condomless sex partners 
(AOR: 2.86; 95% CI: 1.17–6.98) or chemsex (AOR: 2.31; 
95% CI: 1.09–4.91). Conclusion: This bio-behavioural 
study of MSM found high rates of behaviours asso-
ciated with increased risk of HIV transmission. 
Combination prevention, including frequent HIV test-
ing and use of PrEP, remains crucial in London.
Introduction
Combination prevention is an effective approach to 
address the HIV epidemic, but requires implementa-
tion of a range of interventions including condom use, 
high levels of HIV testing, early initiation of antiret-
roviral therapy (ART) and, more recently, appropriate 
pre-exposure prophylaxis (PrEP) use in populations at 
higher risk of HIV [1-3].
In the United Kingdom (UK), men who have sex with 
men (MSM) remain the population at highest risk of 
acquiring HIV. In 2016, there were 2,236 new HIV diag-
noses among MSM in England, of those nearly half 
(49%; 1,096) lived in London [4]. Of all MSM living with 
HIV in the UK, one in 10 were estimated to be unaware 
of their HIV infection status in 2016 compared with one 
five in 2010 [5,6]. Significant declines in the number 
of new diagnoses in MSM attending sexual health (SH) 
clinics in London have been observed between 2014 
and 2015 and attributed to increased repeat HIV testing 
alongside decreased time between HIV diagnosis and 
initiation of ART as well as increased use of PrEP [7,8]. 
More frequent testing in MSM is also likely to result in 
earlier diagnosis, decreasing the time from infection to 
suppressive treatment and thereby preventing onward 
transmission.
Rates of HIV testing in the MSM population in the UK 
are high and increasing. In London, the Gay Men’s 
Sexual Health survey (GMSHS) allowed us to observe 
that the proportion of men reporting having had an 
HIV test in the last year increased from 26% in 2000 to 
60% in 2013 [9]. National guidelines recommend that 
MSM should test annually and those having condom-
less anal sex with new or casual partners should have 
an HIV test every 3 months [6,10]. Rates of condomless 
sex have increased, with 43% of MSM participating in 
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the GMSHS reporting condomless anal intercourse in 
the previous 12 months in 2000 compared with 53% in 
2013 [9].
PrEP is highly effective in protecting individuals from 
HIV acquisition, [11,12]; however, at the time of this 
study it was not provided by the National Health 
Service (NHS) in England and could only be sourced via 
private prescriptions or bought online. For those sourc-
ing PrEP privately, the recommended clinical monitor-
ing before initiating and while on PrEP was provided 
by some NHS SH services. Since the time of this study 
PrEP has become available free of charge to 26,000 
eligible people through the PrEP IMPACT trial, enrol-
ment for which began through SH clinics in England in 
October 2017 [13].
There is a lack of current data on the rate of PrEP use 
among MSM in London alongside other measures of 
combination prevention including condom use and HIV 
testing which are crucial to understand the impact and 
implementation of combination prevention in MSM in 
this city. We report the latest iteration in 2016 of the 
London GMSHS, a community-based questionnaire 
survey of MSM conducted periodically since 1997 (last 
conducted in 2013) which has included the collection 
of anonymous oral fluid specimens to allow testing for 
HIV since 2000 [9]. The aim of this survey was to better 
understand the prevention needs of MSM in London by 
estimating the diagnosed and undiagnosed HIV preva-
lence and identify factors associated with key preven-
tion interventions, such as HIV testing and PrEP use.
Methods
Study population and data collection
Methods used in this cross-sectional study have been 
described previously [9,14] but were adapted for this 
2016 survey. A total of 22 pubs, bars, clubs and sau-
nas in London and Greater London were included in the 
survey, primarily selected from a list of those used in 
previous GMSHS surveys. Internet searches were used 
to identify newer venues and replace those that had 
closed. Of the 59 venues identified, 15 venues, includ-
ing all sex on premises venues and those in areas with 
few venues (North and West London), were approached 
and from the remaining 44 venues, 20 were randomly 
selected and approached. Where possible, venues that 
declined to participate were replaced with a similar 
alternative as geographically close to the original as 
possible.
The paper questionnaire (Supplement S1) was updated 
to include questions on PrEP use and the recognition 
and influence of the London HIV prevention programme 
(LHPP) campaigns which aimed to increase HIV testing, 
condom use and adoption of safer sexual behaviours 
in MSM and people of black African ethnicity.
Participants were recruited between 16 October and 
9 December 2016 by trained fieldworkers who visited 
Table 1
Demographic characteristics study participants, London, 
United Kingdom, 16 October–9 December 2016 (n = 744)
Demographic characteristic   
(total number of respondents with information 
available)
n %
Age group in years (N = 737)
18–24 78 10.6
25–29 169 23.0
30–34 162 22.0
35–39 130 17.6
40–44 84 11.4
45–49 50 6.8
≥ 50 64 8.7
Ethnicity (N = 740)
White 589 79.6
Black 25 3.4
South East Asian 16 2.2
South Asian 26 3.5
Latin American 28 3.8
Mixed 39 5.3
Other 17 2.3
World region of birth (N = 737)
United Kingdom 422 57.3
Rest of Europe 164 22.3
Americas and the Caribbean 66 9.0
Sub-Saharan Africa 14 1.9
South East and East Asia 16 2.2
Other 55 7.5
Currently employed (N = 742)
No 81 10.9
Yes 661 89.1
Education after 16 years of age (N = 740)
None 49 6.6
< 2 years 109 14.7
≥ 2 years 547 73.9
Still in full time education 35 4.7
Last condomless sex (N = 685)
Last 3 months 412 60.1
3–12 months ago 113 16.5
> 12 months ago 160 23.4
Number of casuala condomless partners in the last 12 months (N = 508)
0 207 40.8
1 155 30.5
2–4 73 14.4
5–10 41 8.1
≥ 11 32 6.3
Had an STI in the last 12 months (N = 743)
No 596 80.2
Yes 147 19.8
Chemsexb in the last 12 months (N = 744)
No 590 79.3
Yes 154 20.7
Had used PrEP in the last 12 months (N = 744)
No 698 93.8
Yes 46 6.2
Venue of recruitment (N = 741)
Bar/pub 522 70.5
Club 172 23.2
Sauna 47 6.3
PrEP: pre-exposure prophylaxis; STI: sexually transmitted infection.
a Casual partner is defined as a partner with whom the respondent has had sex with only once.
b Chemsex is defined as use of any of the following drugs before or during sex: 
gammahydroxybutrate (GHB) ketamine, mephadrone, or methamphetamine in the previous 
12 months.
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venues multiple times over a range of pre-arranged 
dates and times. The purpose of the survey, oral 
fluid collection and inclusion criteria were explained 
to potential participants, information sheets were 
provided and verbal consent was obtained. All data 
were collected anonymously and information on how 
to access named testing was included in the infor-
mation sheet. Men who were aged 18 years and over, 
identified as gay or bisexual or who had had sex with 
a man within the last year were eligible to participate. 
Individuals completed the questionnaire themselves 
and placed it into the tamper-proof envelope provided.
Oral fluid collection and device validation
All participants were invited to provide an oral fluid 
specimen including those who knew their HIV status 
to be positive. Fieldworkers were trained to explain 
that even when positive status was already known, 
obtaining samples would enable estimation of overall 
prevalence as well as undiagnosed HIV prevalence. 
Oral fluid specimens were collected using the Intercept 
i2heTM (Orasure Technologies) device which replaced 
the OraSure kitTM devices used in previous surveys as 
these were no longer available in the European Union. 
The unmarked device was placed under the tongue 
for between 2 and 15 min until the indicator changed 
colour. Completed specimen tubes were sealed and 
placed into tamper-proof envelopes with the completed 
questionnaire. All specimens were transported to the 
National Infections Service, London within 7 days of 
collection to ensure they were processed within the 
21-day ambient storage window. Specimens were 
tested for HIV antibody using the in-house IgG anti-
body-capture enzyme-linked immunosorbent assay 
(GACELISA) assay. Reactive specimens (optical den-
sity/cut off ratio (OD/CO) > 1.0) were presumed reactive, 
repeat tested and confirmed by western blot. All speci-
mens were tested for total IgG concentration to ensure 
specimen quality and specimens with < 0.2 mg/L IgG 
were excluded from the results. All GACELISA HIV anti-
body negative specimens from participants reporting 
their HIV status as positive were submitted for western 
blot testing to confirm the GACELISA result.
The new oral fluid collection device was validated 
to ensure comparable performance of the GACELISA 
assay with previous surveys that used the Orasure 
kitTM collection device. A total of 119 specimens (102 
from known HIV positive patients and 17 from known 
negative PHE staff volunteers) were collected and 
tested for total IgG concentration and HIV antibodies. 
Of the negative specimens all had CO/OD of < 1.0, of 
the positive specimens one was excluded due to low 
IgG (concentration < 0.2 mg/L) and of the rest 92.1% 
(93/101) had CO/OD > 1.0. These results were similar to 
devices employed in previous GMSHS and thus suffi-
cient to proceed with the Intercept i2heTM for the 2016 
surveys.
Ethical approval
Ethical approval for the study was granted by the 
London Harrow Research Ethics Committee (REC refer-
ence 00/0158).
Statistical analysis
Data were double entered into a Microsoft Access 2010 
database and validated and analysed in Stata v13.1. 
Binary logistic regression was used to analyse associa-
tions between demographic and behaviour variables 
and the primary outcomes. Crude odds ratios (OR) 
were calculated and associations with a p value < 0.10 
were included in the multivariate regression mod-
els. Associations are reported as OR or adjusted OR 
(AOR) with 95% confidence intervals (CI) and p values. 
Participants reporting their status as HIV positive and 
not testing in the past year were excluded from analy-
ses on HIV testing. Collected variables were combined 
to create the derived variables of chemsex (partici-
pants who answered yes to using ketamine, mepha-
drone, gammahydroxybutrate or methamphetamine 
before or during sex) and frequent testers (participants 
that recorded two or more HIV tests in the previous 
12 months).
Results
Questionnaires were collected from 767 men of whom 
23 were excluded either because they did not self-iden-
tify as MSM (n = 18) or had already participated in the 
survey (n = 5); the remaining 744 men were included 
in the following analyses. The median age of partici-
pants was 33 years (interquartile range (IQR): 20–65) 
and the majority were of white ethnicity (79.6%), UK 
born (57.3%), in current employment (89.1%) and had 
2 or more years of education after the age of 16 years 
(73.9%). A total of 412 (60.1%) men reported condom-
less anal sex within the previous 3 months and a similar 
proportion (59.3%; i.e. 301/508 with information avail-
able) reported at least one casual condomless anal 
sex partner in the previous 12 months. In the previous 
12 months, a total of 46 (6.2%) reported using PrEP, 
147 (19.8%) reported having being diagnosed with a 
sexually transmitted infection (STI) and 154 (20.7%) 
reported engaging in chemsex (Table 1). There were no 
significant differences between men recruited in dif-
ferent venue types but saunas had the highest propor-
tion of men over 50 years old (22.2%; 10/45) compared 
with clubs and bars/pubs where 5.3% (9/169) and 8.5% 
(44/520) were aged over 50 years respectively.
Oral fluid results and undiagnosed HIV
Of the 744 men included in this analysis, 585 (78.5%) 
provided an oral fluid specimen. Of these, six (1.03%) 
had total IgG concentrations too low for testing and 
a further 34 (5.8%) were excluded due to a labora-
tory processing error leaving 545 for analysis. A total 
of 38 (7.0%) specimens were positive for HIV 1 anti-
bodies. Self-reported HIV status and oral fluid results 
were compared and of the 474 men who reported their 
HIV status as negative, five (1.0%) were HIV antibody 
positive indicating undiagnosed HIV infections. Of all 
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Table 2
Logistic regression analyses to assess the association of certain characteristics with reporting two or more HIV tests in the 
last 12 monthsa,b, London, United Kingdom, 16 October–9 December 2016
Characteristic 
 
(total number of respondents with 
information available)
n %
Univariate analysis Multivariate analysisi
OR (95% CI) p value AOR (95% CI) p value
Age category in years (N = 663)
18–24 (n = 69) 41 59.4 Reference
<0.001
Reference
0.003
25–34 (n = 306) 170 55.5 0.85 (0.50–1.45) 0.61 (0.30–1.23)
35–44 (n =191) 78 40.8 0.47 (0.27–0.83) 0.34 (0.16–0.72)
≥ 45 (n = 97) 33 34.0 0.35 (0.19–0.67) 0.29 (0.12–0.69)
Ethnicity (N = 664)
White (n = 523) 247 47.2 Reference
0.255
NA
NA
Black (n = 24) 13 54.2 1.32 (0.58–3.00) NA
South East & East Asian (n = 39) 24 61.5 1.79 (0.92–3.49) NA
Latin American (n = 26) 13 50.0 1.12 (0.51–2.46) NA
Other (n = 52) 27 51.9 1.21 (0.68–2.13) NA
World region of birth (N = 662)
United Kingdom (n = 379) 177 46.7 Reference
0.184
NA
NA
Europe (n = 146) 72 49.3 1.11 (0.76–1.63) NA
Americas & Caribbean (n = 61) 34 55.7 1.44 (0.83–2.48) NA
Sub-Saharan Africa (n = 12) 10 83.3 5.71 (1.23–26.39) NA
South East & East Asia (n = 26) 15 57.7 1.56 (0.70–3.48) NA
Other (n = 38) 17 44.7 0.92 (0.47–1.81) NA
Employment status (N = 666)
Employed (n = 603) 302 50.0 1.74 (1.02–2.99) 0.006 1.28 (0.61–2.66) 0.137
Years of education after 16 years of age (N = 664)
None (n = 36) 18 50.0 Reference
0.973
NA
NA
< 2 years (n = 98) 48 49.0 0.960 (0.447–2.061) NA
≥ 2 years (n = 498) 244 49.0 0.961 (0.488–1.890) NA
Still in full time education (n = 32) 14 43.8 0.778 (0.299–2.024) NA
Had an STI in the last year (N = 667)
Yes (n = 122) 99 81.0 6.08 (3.74–9.86) <0.001 5.05 (2.66–9.58) <0.001
Number of casualc condomless partners in last year (N = 456)
0 (n = 194) 75 38.7 Reference
<0.001
Reference
0.010
1 (n = 144) 67 46.5 1.38 (0.89–2.14) 1.26 (0.79–2.02)
2–4 (n = 65) 48 73.8 4.48 (2.40–8.36) 3.65 (1.87–7.10)
5–10 (n = 33) 25 75.8 4.96 (2.13–11.57) 3.34 (1.32–8.49)
> 10 (n = 20) 18 90.0 14.28 (3.22–63.31) 9.47 (1.92–46.62)
Chemsexd (N = 668)
Yes (n = 132) 81 61.0 1.90 (1.289–2.81) 0.005 1.23 (0.70–2.14) 0.572
PrEP use (N =  660)
Yes (n = 37) 30 81.0 4.89 (2.12–11.30) <0.001 1.75 (0.64–4.77) 0.046
AOR: adjusted odds ratio; CI: confidence interval; NA: not applicable; OR: odds ratio; PrEP: pre-exposure prophylaxis; STI: sexually 
transmitted infection.
a 32 men who self-reported as HIV positive and had not had a test within the last year were excluded from this analysis.
b Adjusted model contains a total of 447 observations.
c Casual partner is defined as a partner with whom the respondent has had sex with only once.
d Chemsex is defined as use of any of the following drugs before or during sex; mephadrone, ketamine, gammahydroxybutrate (GHB) or 
methamphetamine in the last 12 months.
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those with HIV antibody positive oral fluid specimens 
in this study population (n = 38), five men (13.2%; 
95% CI: 2.4–24.0%) were unaware of their infection and 
had reported their status as negative. Of the 35 men 
who self-reported as HIV positive, four (11.5%) were 
HIV antibody negative on both the GACELISA and west-
ern blot assays likely indicating reduced oral fluid test 
sensitivity in the setting of longstanding ART [15].
Men who reported their status as HIV positive were sig-
nificantly less likely to provide a specimen than men 
reporting their status as negative with rates of 61.4% 
(35/57) and 78.5% (474/604) respectively (p = 0.005).
HIV testing
Rates of HIV testing were high with 96.2% (710/738) 
of men reporting ever having an HIV test and 69.7% 
(514/738) having had a test in the previous 12 months. 
The number of HIV tests undertaken in the previous 
year was reported by 700 men; In order to eliminate 
from the analysis those who had not had an HIV test 
because they know they are positive, men who reported 
their status to be positive and had not had a test in the 
last year were excluded, leaving a total of 668 men. Of 
these, 86 (12.9%) reported having four or more tests. 
Of the 125 HIV negative men who reported two or more 
casual condomless partners in the previous 12 months, 
57 (45.6%) reported four or more HIV tests in the same 
time period. The majority of men, 77.0% (565/734) 
reported attending a SH clinic for their last HIV test.
The proportion of men who reported having two or more 
HIV tests in the last 12 months was 48.7% (325/668). 
Multivariate logistic regression analysis comparing men 
reporting two or more tests with those reporting fewer 
than two in the previous 12 months, revealed that men 
aged 35 years and over were significantly less likely to 
have tested more than once compared with younger 
men (AORs: 0.34 and 0.29 for MSM aged 35–44 years 
and ≥45 years respectively). Men diagnosed with an 
STI in the previous 12 months were significantly more 
likely to report frequent HIV testing (AOR: 5.05) than 
those not reporting an STI. Men reporting between 
more than two casual condomless partners in the pre-
vious 12 months (AORs: 3.65, 3.34 and 9.47 for MSM 
having 2–4, 5–10 and >10 such partners respectively) 
were also more likely to report frequent testing com-
pared with men reporting one or no casual condomless 
partner in the previous 12 months. Frequency of test-
ing was not associated with ethnicity, world region of 
birth, employment status, years of education, chemsex 
participation or PrEP use (Table 2).
Pre-exposure prophylaxis use
Overall, 46 of the 744 MSM (6.2%) reported using 
PrEP in the previous 12 months of whom 24 were using 
PrEP at the time of the survey. A total of 13 men did 
not report their source of PrEP, but of those that did 
(n = 33), the most frequently reported source was the 
Internet with 14 buying it online. Concerning the past 
12 months, six PrEP users reported not having attended 
a SH clinic and five reported not having an HIV test. 
Of the 492 men for whom we had a negative oral fluid 
result and data on the last condomless sex and PrEP 
use, 463 reported not using PrEP. Of these, 274 (59.2%) 
reported condomless sex in the previous 3 months.
In the multivariate analysis men reporting two or more 
casual condomless partners (AOR: 2.86) or chemsex in 
the last year (AOR: 2.31) were significantly more likely 
to have used PrEP. In the univariate analysis, those who 
reported having one or more STI diagnoses in the pre-
vious 12 months were more likely to report using PrEP 
(21/143; 14.7%) than those who had not been diag-
nosed with an STI (25/588; 4.3%) (OR: 3.88); but the 
association did not remain in the multivariate model 
(AOR: 1.58; 95% CI: 0.72–3.45). Men reporting two or 
more HIV tests in the last year was also significantly 
associated with PrEP use in the univariate analysis, but 
there was no evidence of association in the multivari-
ate analysis (AOR: 2.13; 95% CI: 0.93-4.88). There were 
no significant differences in PrEP use by age, ethnic-
ity, education level, employment status or serosorting 
behaviour (Table 3).
Discussion
This bio-behavioural study of MSM in London found 
high rates of behaviours associated with increased risk 
of HIV transmission. Most men (60.1%) reported con-
domless sex in the last 3 months; most (59.3%) had 
had condomless sex with at least one casual partner 
in the previous 12 months; one in five reported having 
an STI in the previous 12 months; and one in five men 
reported chemsex in the last year, higher than most 
estimates observed in other studies [16-19]. Despite 
this, the number of new diagnoses in MSM in London 
is falling and according to estimates from surveillance 
data, rates of undiagnosed infection have decreased 
from 18% in 2013 to 10% in 2016 [5,20]. Given the 
absence of change in sexual risk behaviours these 
decreases signal that biomedical prevention initiatives 
may be having a greater impact on the incidence of new 
infections. While the sample size for detecting undiag-
nosed infection is small in this study, we observed that 
13.2% (95% CI: 2.4–23.9) of men living with HIV were 
unaware of their infection.
The population of MSM surveyed demonstrated high 
awareness of the importance of regular testing. Nearly 
all men (96.2%) reported ever having an HIV test and 
unprecedented rates of men reported having had a test 
in the previous 12 months (69.7%) in line with patterns 
reported elsewhere [7]. MSM reporting condomless sex 
with large numbers of causal partners (i.e. > 10) were 
more likely to report more frequent testing. However, 
men who were older were less likely to report frequent 
testing and men reporting PrEP or chemsex use were 
no more likely to report two or more tests in past year 
than men not reporting PrEP or chemsex use (although 
this should be interpreted with caution as we were not 
powered to detect this). This suggests that there are 
important subgroups of MSM for whom greater efforts 
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to promote messages of regular testing should be 
reinforced, including those reporting the highest risk 
behaviours. The findings on frequency of testing are 
particularly relevant in the light of recent decreases in 
HIV diagnoses in MSM in London and in this study half 
(48.7%) of the men reported having had more than one 
HIV test in the last year. In addition, MSM having regu-
lar HIV tests are also more likely to test for and there-
fore be diagnosed with other STIs, reducing duration of 
infection and thus onward transmission of other STIs.
While 12.9% of men reported having four or more tests 
in the previous 12 months, in keeping with national 
guidance for HIV testing in MSM at higher risk of HIV, 
less than half (45.6%) of those reporting two or more 
casual condomless partners reported testing four or 
more times in the same time period. We did not ask 
about timing of risk behaviours and testing but these 
findings suggest that further progress is required 
to increase the rate of frequent testing for all men at 
higher risk of HIV acquisition. A lower than recom-
mended frequency of testing in at risk MSM has also 
been reported from three other surveys in the UK 
between 2011 and 2013 [21].
Some men at higher risk of HIV infection are self-
selecting PrEP as an option for HIV prevention. The rate 
of PrEP use reported here (6.2%) is within the range 
Table 3
Logistic regression analyses to assess the association of certain characteristics with self-reported pre-exposure prophylaxis 
use in the previous 12 monthsa, London, United Kingdom, 16 October–9 December 2016
Characteristic 
 
(total number of respondents with information 
available)
n %
Univariable analysis Multivariable analysis
OR (95% CI) p value AOR (95% CI) p value
Age category in years (N = 725)
< 25 (n = 77) 5 6.5 Reference
0.885
NA
NA25–39 (n = 452) 30 6.6 1.02 (0.38–2.73) NA
≥ 40 (n = 196) 11 5.6 0.86 (0.29–2.55) NA
Ethnicity (N = 729)
White (n = 582) 33 5.7 Reference
0.161
NA
NA
Non-white (n = 147) 13 8.8 1.61 (0.83–3.15) NA
Year of education after 16 (N = 728)
None (n = 44) 4 9.1 Reference
0.631
NA NA
< 2 years (n = 105) 4 3.8 0.40 (0.09–1.66) NA NA
≥ 2 years (n = 545) 36 6.6 0.71 (0.24–2.09) NA NA
Still in education (n = 34) 2 5.9 0.63 (0.11–3.63) NA NA
Employment status (N = 730)
Employed (n = 652) 40 6.1 0.78 (0.32–1.91) 0.594 NA NA
Tested two or more times in last year (N = 692)
Yes (n = 323) 30 9.3 4.10 (1.91–8.76) <0.001 2.13 (0.93–4.88) 0.074
Number of casualb condomless partners in last year (N = 506)
0 (n = 206) 9 4.4 Reference
<0.001
Reference
0.0071 (n = 154) 4 2.6 0.58 (0.18–1.93) 0.60 (0.18–2.07)
 ≥ 2 (n = 146) 24 16.4 4.31 (1.94–9.57) 2.86 (1.17–6.98)
Chemsexc (N = 732)
Yes (n = 153) 23 15.0 4.28 (2.33–7.86) <0.001 2.31 (1.09–4.91) 0.030
Had an STI in last year (N = 731)
Yes (n = 143) 21 14.7 3.88 (2.10–7.15) <0.001 1.58 (0.72–3.45) 0.251
Exclusively serosorting (N = 409)
Yes (n = 303) 21 6.9 1.50 (0.55–4.09) 0.424 NA NA
Oral fluid specimen result (N = 537)
Ab negative (n = 500) 29 5.8 Reference
0.569
NA
NA
Ab positive (n = 37) 3 8.1 1.43 (0.42–4.95) NA
Ab: antibody; AOR: adjusted odds ratio; CI: confidence interval; NA: not applicable; OR: odds ratio; PrEP: pre-exposure prophylaxis; STI: 
sexually transmitted infection.
a Adjusted model contains a total of 480 observations.
b Casual partner is defined as a partner with whom the respondent has had sex with only once.
c Chemsex is defined as use of any of the following drugs before or during sex; mephadrone, ketamine, gammahydroxybutrate (GHB) or 
methamphetamine in the last 12 months.
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observed in two previous studies measuring PrEP use 
in MSM in England, which found 2.1% and 8% of par-
ticipants had or were currently using PrEP respectively 
[22,23]. It is important to note that the numbers of men 
reporting PrEP use was small in this study, and with 
a larger sample size some associations found to be 
significant in the univariate model may have remained 
significant in the multivariate model. PrEP use in this 
study was associated with increased rates of casual 
condomless anal sex partners and use of drugs associ-
ated with chemsex, suggesting that those using PrEP 
are likely to be assessing their own need correctly. 
Those reporting STI diagnoses in the past year were 
significantly more likely in univariate analysis to use 
PrEP, but this association disappeared once other fac-
tors such as chemsex were controlled for in the multi-
variate model. Since we did not ask about the number 
of STI tests individuals had, we do not know from this 
study if the increased STIs’ rates are indicative of more 
frequent testing or because PrEP users are more likely 
to exhibit risk factors related to higher levels of STI 
transmission. The PROUD PrEP trial [11] found higher 
rates of STIs in the PrEP intervention arm, though they 
were high in both arms, and the difference was not 
significant once STI testing rates were controlled for. 
However, men enrolled in the Amsterdam PrEP imple-
mentation trial had a significantly higher hepatitis C 
virus (HCV) infection prevalence than those in the gen-
eral population of HIV negative MSM attending SH ser-
vices [24].
In our study, a small proportion of those reporting PrEP 
use in the last year had not had an HIV test in the same 
time period and PrEP use was not associated with fre-
quent testing in either multivariate model. It is a con-
cern that those using PrEP from other sources than SH 
clinics, such as online may not be accessing the clini-
cal monitoring recommended for safe PrEP use and the 
early detection of other STIs such as HCV [25]. PrEP use 
in England is evolving rapidly and will have changed 
since this study was conducted, not least as a result 
of the PrEP implementation trial (IMPACT) which began 
recruiting in October 2017 [13]. While data on eligibility 
for PrEP use were not collected in this study, we found 
59.2% of HIV-negative men reported recent condom-
less sex. While imprecise, this may be a broad indica-
tion of the proportion of men in this study population 
who could have benefitted from PrEP.
Study limitations include that convenience sampling 
was conducted in a range of pre-agreed social venues. 
The men using these venues are unlikely to be repre-
sentative of all MSM in London and those participat-
ing in the survey may not be representative of all MSM 
in those venues. MSM in convenience samples tend 
to be younger, more likely to identify as gay and more 
likely to report more sexual risk behaviours than MSM 
in probability samples [26]. The cross-sectional study 
design used here makes it difficult to infer the tem-
poral association between risk factors and outcomes. 
Response rates were not collected systematically and 
are not recorded here, collected rates ranged from 44% 
to 100%. There was a discrepancy between the likeli-
hood of men providing an oral fluid sample based on 
their HIV status and four men self-reporting their sta-
tus as HIV positive did not have anti-HIV detected by 
the oral fluid specimen assay likely due to reduced 
oral fluid test sensitivity in those on longstanding 
ART. Preparatory validation work found a sensitivity of 
92.1% therefore a small number of false positives were 
expected, these rates are acceptable for epidemiologi-
cal studies but not for diagnostic work.
In conclusion, this study suggests that uptake of com-
bination HIV prevention appears to be higher than in 
previous reports among MSM in London. Higher rates 
of repeat HIV testing, some evidence of decreased 
prevalence of undiagnosed HIV infection and the use of 
PrEP by some MSM engaging in higher risk behaviours 
are all likely to be linked to fewer HIV diagnoses. The 
IMPACT trial will increase the number of MSM using 
PrEP which should reduce HIV transmission further. 
However, results from these analyses also demonstrate 
that there is a continued need to reinforce messages 
about HIV testing and behavioural risk reduction for 
all MSM. Condom use continues to play an important 
role in HIV and other STI prevention among MSM and 
should remain a key component of health promotion 
messages. Further work is required to investigate and 
overcome the barriers to testing and condom use that 
still exist for some men and to ensure that the poten-
tial successes of combination prevention are repeated 
in all communities and all areas of the country.
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